Drugs / piclozotan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00272909 | Sep 2004 → Oct 2006 | stroke disorder | Daiichi Sankyo | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00623363 Comparator | Jul 2007 → Jul 2008 | Parkinson disease | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piclozotan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00272909 ↗ |
| Known as | SUN-N-4057 | ChEMBL registry synonym — accepted as the source's own label CHEMBL345237 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL345237 ↗ |
| Modality | Small molecule | — CHEMBL345237 ↗ |
| Route | Intravenous | “Continuous IV infusion over a period of up to 72 hours of piclozotan” NCT00272909 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL345237 ↗ |